Literature DB >> 23131031

Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.

Jennifer Reinboth1, Maria L Ascierto, Nanhai G Chen, Qian Zhang, Yong A Yu, Richard J Aguilar, Rafael Carretero, Andrea Worschech, Yingdong Zhao, Ena Wang, Francesco M Marincola, Aladar A Szalay.   

Abstract

Vaccinia virus (VACV) has emerged as an attractive tool in oncolytic virotherapy. VACV replication efficiency plays a crucial role in the therapeutic outcome. However, little is known about the influence of host factors on viral replication efficiency and permissiveness of a host cell line to infection and oncolysis. In this study, replication of the attenuated VACV GLV-1h68 strain and three wild-type VACV isolates was determined in two autologous human melanoma cell lines (888-MEL and 1936-MEL). Host gene expression and viral gene expression in infected cells were evaluated via respective expression array platforms. Microarray analyses followed by sequential statistical approaches characterized human genes that change specifically due to virus infection. Viral gene transcription correlated with viral replication in a time-dependent manner. A set of human genes revealed strong correlations with the respective viral gene expression. Finally we identified a set of human genes with possible predictive value for viral replication in an independent dataset. The results demonstrate a probable correlation between viral replication, early gene expression, and the respective host response, and thus a possible involvement of human host factors in viral early replication. The characterization of human target genes that influence viral replication could help answer the question of host cell permissiveness to oncolytic virotherapy and provide important information for the development of novel recombinant vaccinia viruses with improved features to enhance replication rate and hence trigger therapeutic outcome.

Entities:  

Mesh:

Year:  2012        PMID: 23131031      PMCID: PMC4015245          DOI: 10.1089/hgtb.2012.057

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  58 in total

Review 1.  hnRNP complexes: composition, structure, and function.

Authors:  A M Krecic; M S Swanson
Journal:  Curr Opin Cell Biol       Date:  1999-06       Impact factor: 8.382

2.  High-fidelity mRNA amplification for gene profiling.

Authors:  E Wang; L D Miller; G A Ohnmacht; E T Liu; F M Marincola
Journal:  Nat Biotechnol       Date:  2000-04       Impact factor: 54.908

3.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

4.  The bioenergetic signature of cancer: a marker of tumor progression.

Authors:  José M Cuezva; Maryla Krajewska; Miguel López de Heredia; Stanislaw Krajewski; Gema Santamaría; Hoguen Kim; Juan M Zapata; Hiroyuki Marusawa; Margarita Chamorro; John C Reed
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

6.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  Vaccinia virus WR53.5/F14.5 protein is a new component of intracellular mature virus and is important for calcium-independent cell adhesion and vaccinia virus virulence in mice.

Authors:  Roza Izmailyan; Wen Chang
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

Authors:  Qian Zhang; Yong A Yu; Ena Wang; Nanhai Chen; Robert L Danner; Peter J Munson; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

9.  Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.

Authors:  Stephanie Weibel; Viktoria Raab; Yong A Yu; Andrea Worschech; Ena Wang; Francesco M Marincola; Aladar A Szalay
Journal:  BMC Cancer       Date:  2011-02-14       Impact factor: 4.430

Review 10.  Recent advances in oncolytic virus design.

Authors:  Rubén Hernández-Alcoceba
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.340

View more
  2 in total

Review 1.  Monitoring the Efficacy of Oncolytic Viruses via Gene Expression.

Authors:  Ashley Ansel; Joshua P Rosenzweig; Philip D Zisman; Beni Gesundheit
Journal:  Front Oncol       Date:  2017-11-06       Impact factor: 6.244

2.  Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy.

Authors:  Dana Haddad; Nicholas Socci; Chun-Hao Chen; Nanhai G Chen; Qian Zhang; Susanne G Carpenter; Arjun Mittra; Aladar A Szalay; Yuman Fong
Journal:  Mol Ther Oncolytics       Date:  2016-03-16       Impact factor: 7.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.